Skip to main content
Clinical Trials/NCT01241656
NCT01241656
Completed
Not Applicable

Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1

University of North Carolina, Chapel Hill2 sites in 1 country2,521 target enrollmentJanuary 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy Men Age 50 Who Are Considering PSA Screening
Sponsor
University of North Carolina, Chapel Hill
Enrollment
2521
Locations
2
Primary Endpoint
PSA test vs. No PSA test
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

In this study we will compare 3 strategies for systematic delivery of prostate cancer screening decision support interventions (DESI) to usual care and examine their impact on screening decisions and subsequent healthcare utilization using a randomized control design.

We hypothesize men who are given the opportunity to review a DESI by one of the 3 strategies will be less likely to opt for prostate cancer screening, and will have lower subsequent healthcare utilization than men in the control group.

Detailed Description

We will use a randomized experimental design to compare the effects of 3 different strategies to implement a prostate cancer screening decision support intervention (DESI) with a control condition in primary care in 2 clinical systems - PAMF (Palo Alto Medical Foundation) and UNC. The primary outcomes of interest are men's screening decisions and their subsequent healthcare utilization. Secondary outcomes include the likelihood that they review the DESI and their decision-specific knowledge. The 3 strategies selected by the PAMF and UNC health systems are: (1) mailing men a DESI in DVD; (2) inviting men to participate in a shared (group) medical appointment (SMA) to watch and discuss the DESI with a healthcare provider and other men; and (3) providing men options by inviting them to a SMA while also providing them a DESI in DVD which they can use individually if they are unable or choose not to attend a SMA. The 3 groups will be compared to a control condition that does not receive a DESI but will be encouraged to discuss prostate cancer screening with their physician. Because of its significantly larger patient population, the PAMF site will also evaluate these outcomes by targeting screening-naïve patients on their 50th birthday, when they first become guideline eligible to consider prostate cancer screening.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
December 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Carmen Lewis, MD, MPH

Associate Professor

University of North Carolina, Chapel Hill

Eligibility Criteria

Inclusion Criteria

  • age 50 or older
  • do not have a prostate diagnosis
  • have not had a PSA test in the past 10 months
  • have not seen their primary care physicians in the last 3 months

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

PSA test vs. No PSA test

Time Frame: 12 month follow-up

We will determine whether a DESI viewing had an impact on testing.

Healthcare utilization and costs

Time Frame: 12 month follow-up

All prostate specific health care utilization and cost will be estimate for each group.

Secondary Outcomes

  • Decision specific knowledge(4 months after mailings)
  • Discussion with provider(4 months after mailings)
  • DESI viewing(4 months after mailings)

Study Sites (2)

Loading locations...

Similar Trials